Actinium Pharmaceuticals, Inc.
ATNMHealthcare|Biotechnology|US
$1.43
+0.13 (+10.00%)
DCF Value
$1.48
Tangible Book / Share
$0.97
Graham Number
$2.80
Cash / Share
$1.16
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT02665065 Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, Leukemia, Acute Myeloid | P3 | Active | 153 | RCT, Open-label | Iomab-B, Conventional Care |
| NCT06768905 IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | P1P2 | Recruiting | 30 | Open-label | Iomab-B, CAR-T cell |
| NCT07015684 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) | Sickling Disorder Due to Hemoglobin S | P1 | Recruiting | 24 | Open-label | 131I-apamistmab, Sirolimus, Campath |
| NCT07157514 Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | Acute Leukemia, Myeloid Leukemia | P2P3 | Not Yet Recruiting | 306 | RCT, Open-label | 131I-apamistamab, Fludarabine, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplant (HSCT) |
| NCT03932318 Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | Acute Myeloid Leukemia, Relapsed Adult AML | P1P2 | Withdrawn | — | Open-label | Lintuzumab-Ac225, Venetoclax, Azacitidine |
| NCT03867682 Venetoclax and Lintuzumab-Ac225 in AML Patients | Acute Myeloid Leukemia, Relapsed Adult AML | P1P2 | Unknown | 38 | Open-label | Lintuzumab-Ac225, Venetoclax, Spironolactone |
| NCT02575963 Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | AML | P1P2 | Completed | 40 | Open-label | Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only), Spironolactone |
| NCT02998047 A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | Refractory Multiple Myeloma | P1 | Terminated | 2 | Open-label | Lintuzumab AC 225 |
| NCT00672165 Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies | Leukemia, Myelodysplastic Syndrome | P1 | Completed | 23 | Open-label | ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 |